The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors

Endocrine-Related Cancer

Volumn 17, Issue 4, 2010, Pages 897-908

  Figueroa Vega, Nicté ^a,b,c   Díaz, Ángel ^d   Adrados, Magdalena ^a   Álvarez Escolá, Cristina ^e   Paniagua, Amalia ^a   Aragonés, Julián ^a   Martín Pérez, Elena ^a   Leskela, Susanna ^a   Moreno Otero, Ricardo ^a   González Amaro, Roberto ^b   Marazuela, Mónica ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c UNIVERSITY OF GUANAJUATO   (Mexico)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CHROMOGRANIN A;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; LEUKOCYTE MIGRATION; LIVER METASTASIS; MALE; MONOCYTE; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; CHEMOTAXIS; CHROMOGRANIN A; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; HYDROXYINDOLEACETIC ACID; IMMUNOHISTOCHEMISTRY; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROSPECTIVE STUDIES; RECEPTOR, TIE-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; STATISTICS, NONPARAMETRIC;

EID: 78649862825     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0020     Document Type: Article

References (41)

1. Cao Y, Sonveaux P, Liu S, Zhao Y, Mi J, Clary BM, Li CY, Kontos CD & Dewhirst MW 2007 Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Research 67 3835-3844. (doi:10.1158/0008-5472.CAN-06-4056) (Pubitemid 46762171)
2. Carmeliet P 2003 Angiogenesis in health and disease. Nature Medicine 9 653-660. (doi:10.1038/nm0603-653)
3. Chang SH, Kanasaki K, Gocheva V, Blum G, Harper J, Moses MA, Shih SC, Nagy JA, Joyce J, Bogyo M et al. 2009 VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Research 69 4537-4544. (doi:10.1158/0008-5472.CAN-08-4539)
4. De Palma M, Venneri MA, Roca C & Naldini L 2003 Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nature Medicine 9 789-795. (doi:10.1038/nm871)
5. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M & Naldini L 2005 Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8 211-226. (doi:10.1016/j.ccr.2005.08.002)
6. De Palma M, Murdoch C, Venneri MA, Naldini L & Lewis CE 2007 Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends in Immunology 28 519-524. (doi:10.1016/j.it.2007.09.004)
7. De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, Mazzoleni S, Moi D, Venneri MA, Indraccolo S et al. 2008 Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14 299-311. (doi:10.1016/j.ccr.2008.09.004)
8. Detjen KM, Rieke S, Deters A, Schulz P, Rexin A, Vollmer S, Hauff P, Wiedenmann B, Pavel M & Scholz A 2010 Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clinical Cancer Research 16 420-429. (doi:10.1158/1078-0432.CCR-09-1924)
9. Ehehalt F, Saeger HD, Schmidt CM & Grützmann R 2009 Neuroendocrine tumours of the pancreas. Oncologist 14 456-467. (doi:10.1634/theoncologist.2008-0259)
10. Eklund L & Olsen BR 2006 Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Experimental Cell Research 312 630-641. (doi:10.1016/j.yexcr.2005.09.002) (Pubitemid 43290339)
11. Ferrara N & Davis-Smyth T 1997 The biology of vascular endothelial growth factor. Endocrine Reviews 18 4-25. (doi:10.1210/er.18.1.4)
12. Fiedler U & Augustin HG 2006 Angiopoietins: a link between angiogenesis and inflammation. Trends in Immunology 27 552-558. (doi:10.1016/j.it.2006.10.004)
13. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N et al. 2006 Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nature Medicine 12 235-239. (doi:10.1038/nm1351)
14. Figueroa-Vega N, Sanz-Cameno P, Moreno-Otero R, Sánchez-Madrid F, González-Amaro R & Marazuela M 2009 Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features. Journal of Clinical Endocrinology and Metabolism 94 1145-1153. (doi:10.1210/jc.2008-1571)
15. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, Salahuddin N, Korbonits M & Grossman AB 2008 Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 87 168-181. (doi:10.1159/000111501)
16. Haverback B, Sjoerdsma A & Terry L 1956 Urinary excretion of the serotonin metabolite, 5-hydroxylindoleacetic acid, in various clinical conditions. New England Journal of Medicine 255 270-272. (doi:10.1056/ NEJM195608092550605)
17. Jones PF 2003 Not just angiogenesis-wider roles for the angiopoietins. Journal of Pathology 201 515-527. (doi:10.1002/path.1452)
18. La Rosa S, Uccella S, Marchet S, Capella C & Lloyd RV 2003 Localization of vascular endotelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Human Pathology 34 18-27. (doi:10.1053/hupa.2003.56)
19. Lewis CE, De Palma M & Naldini L 2007 Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Research 67 8429-8432. (doi:10.1158/0008-5472.CAN-07-1684)
20. Lobov IB, Brooks PC & Lang RA 2002 Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. PNAS 99 11205-11210. (doi:10.1073/pnas.172161899)
21. Lubensky IA & Zhuang Z 2007 Molecular genetic events in gastrointestinal and pancreatic neuroendocrine tumours. Endocrine Pathology 18 156-162. (doi:10.1007/s12022-007-9007-x)
22. Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E & Plate KH 2004 Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. American Journal of Pathology 165 1557-1570.
23. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N et al. 1997 Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 55-60. (doi:10.1126/science.277.5322.55)
24. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP et al. 2008 Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 9 61-72. (doi:10.1016/S1470-2045(07) 70410-2)
25. Murdoch C, Tazzyman S, Webster S & Lewis CE 2007 Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. Journal of Immunology 178 7405-7411.
26. Niedźwiecki S, Stepień T, Kopeć K, Kuzdak K, Komorowski J, Krupiński R & Stepień H 2006 Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. Cytokine 36 291-295. (doi:10.1016/j.cyto.2007.02.008)
27. Oberg K 2009 Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumours (gastroenteropancreatic neuroendocrine tumours). Current Opinion in Endocrinology, Diabetes, and Obesity 16 72-78. (doi:10.1097/MED.0b013e328320d845)
28. Oxboel J, Binderup T, Knigge U & Kjaer A 2009 Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin alphaV and integrin beta3 in human neuroendocrine tumors. Oncology Reports 21 769-775. (doi:10.3892/or-00000283)
29. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M & Solcia E 1996 Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World Journal of Surgery 20 168-172. (doi:10.1007/s002689900026) (Pubitemid 26069482)
30. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. European Neuroendocrine Tumor Society (ENETS). Virchows Archiv 449 395-401. (doi:10.1007/s00428-006-0250-1)
31. Salcedo X, Medina J, Sanz-Cameno P, García-Buey L, Martín-Vilchez S, Borque MJ, López-Cabrera M & Moreno-Otero R 2005 The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 42 696-701. (doi:10.1002/hep.20828)
32. Shim WS, Teh M, Mack PO & Ge R 2001 Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice. International Journal of Cancer 94 6-15. (doi:10.1002/ijc.1428)
33. Shojaei F, Singh M, Thompson JD & Ferrara N 2008 Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. PNAS 105 2640-2645. (doi:10.1073/pnas.0712185105)
34. Solcia E, Kloppel G & Sobin LH 2000 Histological typing of endocrine tumours WHO International Histological Classification of Tumours. 2nd edn.Eds E Solcia,G Kloppel & LH Sobin. Heidelberg, Germany: Springer Verlag.
35. Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, Caplin ME & Meyer T 2009 Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. Endocrine-Related Cancer 16 967-976. (doi:10.1677/ERC-09-0089)
36. Szekanecz Z & Koch AE 2007 Mechanisms of disease: angiogenesis in inflammatory diseases. Nature Clinical Practice. Rheumatology 3 635-643. (doi:10.1038/ncprheum0647)
37. Thomas M & Augustin HG 2009 The role of the angiopoietins in vascular morphogenesis. Angiogenesis 12 125-137. (doi:10.1007/s10456-009-9147-3)
38. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C & Naldini L 2007 Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109 5276-5285. (doi:10.1182/blood-2006-10-053504)
39. von Wichert G, Edenfeld T, von Blume J, Krisp H, Krndija D, Schmid H, Oswald F, Lother U, Walther P, Adler G et al. 2008 Protein kinase D2 regulates chromogranin A secretion in human BON neuroendocrine tumour cells. Cellular Signalling 20 925-934. (doi:10.1016/j.cellsig.2008.01.003)
40. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL & Ajani JA 2008 Targeting vascular endothelial growth factor in advanced carcinoid tumour: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. Journal of Clinical Oncology 26 1316-1323. (doi:10.1200/JCO.2007.13.6374)
41. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K & Yao JC 2007 Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109 1478-1486. (doi:10.1002/cncr.22554)